NEW YORK – Junshi Biosciences and Impact Therapeutics said on Thursday that they are launching a joint venture to research, develop, and commercialize the PARP inhibitor senaparib (IMP4297) in China.
Under the agreement, both companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications. Junshi Biosciences will contribute up to RMB 300 million ($43.4 million) in cash, and Impact Therapeutics will supply senaparib in Mainland China, Hong Kong, and Macau.